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Abstract
Stricturing and penetrating disease are classified as severe Crohn’s disease types and are frequently associated
with an increased risk for bowel surgery. Research has shown that early treatment with aggressive
immunosuppression (including biological and thiopurine therapies – the so-called “top-down approach”) results in a
diminished risk of developing these complicated disease types. However, these therapies carry significant risks and
cost. Being able to predict which patients are at an increased risk of developing severe Crohn’s disease may enable
us to treat patients individually, with the aggressive “top-down approach” started at diagnosis in patients with a
significantly increased risk of developing complicated disease types. Defects of innate and adaptive immunity both
play a role in Crohn’s disease pathophysiology. Identifying whether defects of innate immunity (through gene
mutations) or adaptive immunity (through antibodies to microbial antigens) are associated with stricturing/penetrating
disease types may enable us to predict the course of the disease and therefore decide on who would benefit most
from the “top-down approach”. This review discusses the role of NOD2 and other gene polymorphisms in predicting
Crohn’s disease severity. It also highlights the evidence linking the role of the various antibodies involved in adaptive
immunity (ASCA, OmpC, GM-CSF) and complicated Crohn’s disease types.
Keywords: Innate immunity; Adaptive immunity; Crohn's disease;
NOD2 polymorphisms; Stricturing disease; Penetreating disease
Introduction
The Montreal classification of inflammatory bowel disease classifies
Crohn’s disease (CD) into three disease types: inflammatory (non-
stricturing, non-penetrating) disease, stricturing disease and
penetrating disease [1]. Stricturing and penetrating disease are
markers of Crohn’s disease severity, being also associated with an
increased risk of surgical intervention [2,3]. CD is a dynamic disease
which may progress over time from the non-stricturing, non-
penetrating type of disease to the more severe forms of this condition.
In a study on CD patients followed up for 25 years, Louis et al. found
that 46% of patients had a change in disease type in the first 10 years of
follow up with 27% of patients developing stricturing disease and 29%
of patients developing penetrating disease [4].
Multiple studies trying to predict which patients with CD are more
prone to develop the more severe (stricturing or penetrating) disease
types have been carried out. Since using potent immunosuppressants
in all CD patients may expose patients with mild CD to an increased
risk of side-effects from these immunomodulators and biological
agents, this approach may help identify which patients would benefit
from aggressive immunosuppression at an early stage. This approach
is frequently called the “top-down” approach and involves starting
intensive therapies, including biological agents (anti-tumor necrosis
factor α agents like infliximab) early on with the aim of avoiding the
development of strictures and fistulas. This approach varies from the
classic “step-up” approach which refers to the progressive
intensification of treatment as the disease becomes more severe.
Studies have shown that the “top-down” approach is better than the
current ”step-up” approach both in the induction and maintenance of
remission, as well as in decreasing the risk of surgery [5].
However, a number of factors still limit the use of anti-tumor
necrosis factor (TNF) α therapy in all CD patients. These factors
include potential side-effects associated with this therapy, including
risks of sepsis secondary to immunosuppression. In addition, up to
50% of patients have mild disease which can be managed adequately
with therapy which is less costly and carries less risks [6]. The
significant cost of anti-tumor necrosis factor (TNF) α agents when
compared with other therapies like aminosalicylates and purine
analogues is another important factor limiting the indiscriminate use
of these agents in all CD patients.
The current challenge in CD is to distinguish at an early stage
patients with an increased likelihood of developing severe disease
types who would therefore benefit from the “top-down” approach. On
the other hand, the “step-up approach” should be used in patients with
predicted mild (inflammatory) disease types. Defects of innate and
adaptive immunity both play a role in CD pathophysiology (Figure 1)
and therefore identifying whether defects of innate immunity (through
gene mutations) or adaptive immunity (through antibodies to
microbial antigens) are associated with stricturing/penetrating disease
types may be used to predict the course of the disease. This may enable
physicians to choose “tailor-made” therapy for their CD patients at the
time of diagnosis.
The biology of Crohn’s disease is well described and involves
various processes involving altered gut permeability, dysfunctional
autophagy and altered immune response. In particular, Atg16l1 and
Nod2 proteins are both necessary for effective autophagy in ileal
Paneth cells and polymorphisms in genes responsible for these
proteins may lead to defective autophagy and intestinal inflammation.
Upon microbial infection of intestinal cells, Nod proteins recruit
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autophagy proteins, including Atg5, Atg12 and Atg16l1, to the plasma
membrane and stimulate the phagosome to engulf the pathogen. The
autophagosome then interacts with the lysosome to break down the
pathogen into bacterial (or viral) peptides. Polymorphisms in the
NOD2 and ATG16L1 genes result in defective autophagy with a hyper
inflammatory response in the intestinal mucosa [7,8].
This review focuses on biomarkers which may be used to predict
the development of delayed complicated disease types in Crohn’s, thus
enabling us to identify which of these patients would benefit most
from early, aggressive immunosuppression.
NOD2/CARD15 Mutations
Evidence that genetics plays an important part in the development
of severe disease types arises from studies in monozygotic and
dizygotic twins in Norwegian inflammatory bowel disease patients.
Data from these studies showed that stricturing disease among twins
was significantly higher than stricturing disease in unrelated CD cases
[9].
The strongest evidence linking gene polymorphisms with
stricturing and penetrating disease types and risk of surgery comes
from mutations in the NOD2/CARD15 pathway. Nucleotide-binding
oligomerization domain-containing protein 2 (NOD2) also known as
caspase recruitment domain-containing protein 15 (CARD15) is
encoded by the NOD2 gene located on chromosome 16. NOD2 plays
an important role in the immune system by recognizing bacterial
peptidoglycans and stimulating the innate immune system [10,11]. At
least 27 polymorphisms in the NOD2/CARD15 gene have been
identified as Crohn’s disease susceptibility genes with the commonest
ones being the R702W and G908R (missense mutations) and the
3020insC and 1007fs (frameshift mutations). Around 40% of CD
patients of Western European and Northern American origin carry at
least one of these variants compared with 0.5-20% of healthy controls
[12].
The NOD family consists of a number of receptors which contain a
nucleotide binding oligomerization domain and a leucine-rich repeat.
These proteins are important in innate immunity since they are able to
recognize pathogen (bacterial, viral) peptides. Upon pathogen
recognition, they activate a specific signal transduction cascade which
leads to a transcriptional response against these pathogens. NOD
proteins are also important in caspase activation and apoptosis. The
leucine-rich repeat allows NOD2 proteins to recognize muramyl-
dipeptide, a component of bacterial wall peptidoglycan, thus leading to
the activation of the autophagy pathway. Autophagy activates an
inflammatory reaction in epithelial cells and releases antimicrobial
peptides from cytosolic granules which degrade bacterial peptides.
Therefore defective NOD2 proteins secondary to NOD2/CARD15
polymorphisms will lead to a defective innate immunity, defective
autophagy and defective handling of intestinal pathogens. These
changes are believed to lead to the increased inflammatory response
seen in patients with CD [13]. NOD2 proteins are found in monocytes,
macrophages, T cells, B cells, Paneth cells, dendritic cells and in
epithelial cells of the small and large intestine.
Mutations in the CARD15 gene have also been shown to have an
effect on intestinal mucosal permeability. A genetically impaired
intestinal barrier function is suspected to lead to the chronic intestinal
inflammation seen in Crohn’s disease. In a study analyzing the
intestinal permeability and CARD15 (R702W, G908R and 3020insC)
polymorphisms in 128 patients with quiescent Crohn’s disease, 129
first degree relatives of Crohn’s patients, 66 non-related household
members and 96 healthy controls, intestinal permeability was
significantly increased in Crohn’s patients and their first degree
relatives when compared with household members and controls. In
addition, 40% of first degree relatives carrying the 3020insC CARD15
mutation and 75% of those relatives with combined 3020insC and
R702W mutations had increased intestinal permeability when
compared with 15% of relatives with the wild-types. These results
suggest that genetic factors may be involved in intestinal barrier
impairment in Crohn’s disease [14].
NOD2/CARD15 mutations are associated with Blau syndrome, a
rare autosomal dominant condition involving granuloma formation,
and possibly also with early onset sarcoidosis. Granuloma formation
occurs secondary to a host reaction to intracellular infections, which
results in the activation of a T helper 1 response with subsequent
production of cytokines (interleukin-12, interferon gamma and tumor
necrosis factor). However, mutations in the NOD2/CARD15 pathway
result in inappropriate activation of the immune system with the
excessive granuloma formation typically seen in these conditions [15].
Genotype-phenotype correlations between these polymorphisms
have shown an association with stricturing and penetrating disease
and an increased risk of surgery in different populations [12,16-27].
Abreu et al. found that patients with NOD2 mutations have nearly a 3-
fold increased risk of developing fibro-stenosing disease when
compared with patients without these polymorphisms [28]. The risk
appears to increase in patients carrying more than one polymorphism
of the NOD2 gene with an odds ratio of sticturing or penetrating
disease of 1.9 in patients with one polymorphism and an odds ratio of
3.5 in patients with two polymorphisms [29]. Patients with multiple
mutations in the NOD2 gene have a younger age at diagnosis, are
associated with more frequent stricturing disease type and less
frequent colonic involvement [30]. Meta-analysis confirmed the
increased risk of complicated CD in patients carrying 2
polymorphisms of the NOD2/CARD15 gene [31].
Patients with one NOD2 polymorphism together with at least one
other risk allele (like interleukin 23 receptor gene, Drosophilia discs
large homologue 5 and autophagy-related 16-like 1 genes,
plasminogen activator inhibitor 1 – IL23R, DLG5, ATG16L1, PAI-1)
also have more severe disease types, more risk for surgery and earlier
disease onset [32-34]. In addition, the need for surgical intervention
appears to be required earlier in patients with these variants [35].
Phenotypic correlation of CD severity with NOD2 mutations was
also confirmed in paediatric populations in several studies [36-38].
These studies confirmed that 2 or more NOD2/CARD15
polymorphisms were strongly associated with need for surgery
secondary to stricturing disease [37,38]. This association appears to be
even stronger for the 3020insC mutation which was shown to carry an
odds ratio of 6.6 for stricturing disease and 5.8 for risk of surgery.
Surgery also appears to occur earlier among children with this
mutation (hazard ratio 2.24) [39].
While NOD2 mutations are the strongest genetic factors
predisposing to small intestinal stricturing CD, cigarette smoking is
the best characterized environmental risk factor predisposing to this
phenotype. In an experiment where intestinal epithelial cells were
exposed to cigarette smoke extract, there was a delayed NOD2 mRNA
expression, reduced nuclear factor kappa Beta (NF-kB) activity and
decreased chemokine production. This suggests that environmental
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factors may also have a direct effect on NOD2 function and NOD2-
mediated responses [40].
While this data may be insufficient to recommend top-down
therapy based on only one NOD2 mutation, the significant risk of
complicated CD associated with two NOD2 mutations or with one
NOD2 mutation and at least one other risk allele may be sufficient to
recommend early-intensive therapy in these patients. Expert
consensus recommendations may in the future be made available once
checking for these polymorphisms becomes more easily available.
Other Genetic Markers
While mutations in the NOD2/CARD15 gene have been most
extensively investigated in the risk of developing severe CD types,
other gene polymorphisms have also been shown to be associated with
stricturing/penetrating disease. In the innate immune system, the
inflammasome plays a central role in maintaining gut homeostasis and
mediating host immune defenses against pathogens (Figure 1). In
Crohn’s disease, dysregulation of the inflammasome contributes to
chronic inflammation and disease onset [41]. Polymorphisms
associated with inflammasome components have in fact been
associated with an increased susceptibility to inflammatory bowel
disease (Table 1). Polymorphisms in IL-18, IL-18 accessory proteins
and NOD-like receptors (NLRs) (which result in impaired IL-1β and
IL-18 production) have all been associated with inflammasome
dysregulation and increased susceptibility to Crohn’s disease [42-44].
Inflammasome formation occurs in a two-step process. In the priming
step, Toll-like receptors (TLRs) induce NF-κB transcription of pro-
Il-1β, pro-Il-18 and NLRs while in the second step, inflammasome
oligomerization leads to cytokine cleavage and mature Il-1β and Il-18
production [45-47]. The potent proinflammatory cytokines Il-1β and
Il-18 can induce T cell differentiation thus bridging innate and
adaptive immune responses [48]. Il-1β also activates the release of
other cytokines, like TNF-α, Il-23 and Il-6 [49]. Il-1β levels are
therefore markers of ongoing inflammation in Crohn’s disease. They
have also been shown to predict early relapse in Crohn’s disease
patients with quiescent disease [50].
The Asp299Gly polymorphism of the Toll-like receptor 4 (TLR4)
gene has been shown to carry a significantly increased risk of
stricturing disease even in the absence of NOD2 polymorphisms while
penetrating disease is more common in patients carrying NOD2
polymorphisms than those with TLR4 polymorphisms [51].
Figure 1: Gene polymorphisms and autoantibodies associated with Crohn’s disease are involved in inflammatory (innate) and adaptive
immune responses. The production of inflammatory cells depend on growth factors as in the case of GM-CSF for neutrophils. Anti-GM-CSF
antibodies suppress the production of neutrophils, hence the decreased bacterial clearance leading to decreased epithelial integrity. Increased
levels of antibodies against specific bacterial peptides are associated with an increased risk of severe Crohn's disease. The most common
mutants in Crohn’s disease, occur in autophagy related genes (susceptibility genes) such as NOD2, which give a prolonged inflammatory
response. In addition, NOD2 is involved in the formation of a TLR4 stimulated inflammasome in dendritic cells, that promotes cleavage of
pro-Ilβ to the active cytokine IL1β, and the production of IL-23 (another susceptibility gene). Other polymorphisms associated with Crohn’s
disease involve genes that are important for the differentiation of CD4+ cells into special T cell subtypes and T cell function. Dysregulation of
IL23R, IL12B, Jak2, Stat3, CCR6 and TNFSF15 through functional polymorphisms, interferes with the pro-inflammatory response involving
Th17 cells which has been shown to have an important role in intestinal inflammation. In addition, Stat3 was also shown to regulate the
inhibitory signals initiated by IL-10 secreted by regulatory T cells (Treg). Hence, autophagy response and Th17 signals are important
mediators of inflammation in Crohn’s disease.
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Polymorphisms within the promoter regions for interleukin-10
(Il-10) and tumor necrosis factor alpha (TNFα) have also been linked
with an increased risk of stricturing disease type [52,53], while TNFα
polymorphisms have been shown to be higher in CD patients with
fistulising disease [54].
Polymorphisms in the clock gene PERIOD3 have been associated
with severe forms of CD. Altered body rhythmicity and deregulated
clock gene expression may lead to circadian disruption, which may
cause immune dysregulation and chronic inflammatory diseases like
CD. PERIOD3 polymorphisms have been associated with circadian
disruption and altered levels of inflammatory cytokines. The
rs2797685 polymorphism of the PERIOD3 gene has been shown to
give an increased risk of stricturing and penetrating disease types (p:
0.03) [55].
Another CD susceptibility gene which has been shown to be
associated with stricturing disease type is the rs7234029 polymorphism
of the protein tyrosine phosphatase, non-receptor type 2 (PTPN2)
gene. This gene appears to regulate autophagosome formation in
intestinal epithelial cells and may therefore form an essential part of
the autophagy pathway [56].
The transforming growth factor beta 1 (TGFbeta1) codon 25 has
variable peptide production, predisposing to fibrosis in several organs.
This codon was associated with stricturing disease (OR=2.63) and
early surgical resection in CD patients [57].
Different gene polymorphisms appear to exhibit different
phenotypic expressions in different populations. Genotype-phenotype
analysis showed an association between the rs1004819 and rs1495465
polymorphisms of the IL23R gene and stricturing/penetrating disease
types among Korean and Finnish CD patients [58,59].
The rs10758669 polymorphism of JAK2 is a CD susceptibility gene
which has been shown to strongly enhance the risk of ileocolonic
disease with stricturing behavior and a significantly elevated risk of
bowel resection in a population of New Zealand CD patients [60].
Other gene mutations may also act as markers of the less severe CD
type. Choosing the “step-up” approach rather than the “top-down”
approach may be justified by finding these polymorphisms in the
absence of biomarkers which predict severe CD types. The IL12B gene
is a susceptibility gene for inflammatory bowel disease which encodes
the p-40 subunit of Interleukin-12. Glas et al. have shown that the
rs6887695 single nucleotide polymorphism of the IL12B gene was
significantly associated with the non-stricturing, non-penetrating CD
type [61]. The RAGE gene (receptor for advanced glycation end
products) is involved in innate immunity and the rs1800624
polymorphism of this gene has also been shown to have a protective
effect against developing the stricturing disease phenotype. This
protective effect probably occurs secondary to an increase in the levels
of serum soluble RAGE (sRAGE) which neutralizes pro-inflammatory
mediators [62].
The genetic markers which predict Crohn’s disease severity are
summarized in Table 1.
Biomarker Polymorphisms Severity of Crohn's Disease References
NOD2 SNP8/R702W
SNP13/G908R
SNP18/1007fs
3020insC
Small bowel Involvement
Fibrostenosing phenotype
Stricturing and penetrating disease
Increased risk for surgery
Abreu et al. [28]
Kugathasan et al. [39]
TLR4 Asp299Gly
Thr399Ile
Stricturing disease Brand et al. [51]
TNFα 857C Stricturing and fistulating disease Fowler et al. [52]
PERIOD3 rs2797685 Stricturing and fistulating disease Mazzoccoli et al. [55]
PTPN2 rs7234029 Stricturing disease Glas et al. [56]
IL10 1082G Stricturing disease Fowler et al. [52]
IL23R rs1004819
rs1495465
Stricturing and penetrating disease Yang et al. [58]
Lappalainen et al. [59]
JAK2 rs10758669 Ileocolonic disease
Stricture formation
Ferguson et al. [60]
IL12B rs6887695 Non-stricturing and
Non-penetrating disease
Glas et al. [61]
RAGE rs1800624 Non-stricturing disease Däbritz et al. [62]
NOD2: Nucleotide-binding Oligomerization Domain-containing protein 2; TLR4: Toll-like Receptor 4; TNFα: Tumor Necrosis Factor alpha; PTPN2: Protein Tyrosine
Phosphatase, Non-receptor type 2; IL10: Interleukin 10; IL23R: Interleukin 23 Receptor complex; JAK2: Janus Kinase 2; IL12B: Interleukin 12 beta; RAGE: Receptor
for Advanced Glycation End products
Table 1: Genetic Markers of Severity in Crohn’s Disease. Key markers involved in innate immune response in Crohn’s disease. Mutations in these
markers are associated with specific severity phenotypes thus lending a prognostic or predictive role in disease management.
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Serological Markers
Research into serological markers of adaptive immunity,
particularly antibodies to bacterial antigens, has also shown an
association with CD phenotype. The most well recognized antibodies
associated with severe CD are antibodies to granulocyte-macrophage
colony-stimulating factor (GM-CSF Ab), Anti-Saccharomyces
cerevisae antibody (ASCA), flagellin (CBir1), and Escherichia coli
anti-outer membrane porin-C (OmpC). Neutralizing autoantibodies
against GM-CSF in children with CD were significantly associated
with structuring ileal CD. Stricturing prevalence on CT enterography
or magnetic resonance enterography (CTE or MRE) increased from
4% in CD patients with low GM-CSF Ab levels (<1.6 μg/mL) to 19% in
those with elevated levels of GM-CSF Ab (≥ 1.6 μg/mL) [63].
These findings were replicated in an independent paediatric CD
cohort which confirmed that the likelihood ratio for stricturing
behavior for patients with elevations in both GM-CSF Ab and GM-
CSF neutralizing capacity was equal to 5. In this cohort, Jurickova et al.
isolated ileal lamina propria mononuclear cells from paediatric CD
patients and controls and showed that these lamina propria cells
produce GM-CSF Ab in the CD patients. Neutrophil bacterial killing
decreased as GM-CSF Ab levels increased confirming the role that
these antibodies play in cellular immunity [64]. The association
between GM-CSF Ab and CD phenotype was subsequently analyzed in
2 independent, predominantly adult CD cohorts. This analysis
confirmed an association between GM-CSF Ab levels and stricturing/
penetrating disease type, and showed an increased risk of intestinal
resection in patients carrying high antibody levels [65].
Oligomannan (Anti-Saccharomyces cerevisae antibody - ASCA) is
one of the best known biomarkers associated with complicated CD
types [66-68]. In a study analyzing predictors of complicated CD in
182 CD patients in the Manitoba IBD cohort, serological and genetic
markers were analyzed at enrolment and after 5 years. Only ASCA-
IgG positive serology was found to be predictive of stricturing/
penetrating disease behavior and surgery [69]. ASCA antibodies were
also found to be predictive of ileal involvement, complicated disease
behavior (stricturing/penetrating disease type) and surgery among
African-American CD patients [70].
The microbial antigen CBir1 (flagellin) produces strong adaptive
immune responses in mouse models of colitis. Antibodies against this
antigen have been shown to be associated with small-bowel disease,
penetrating disease and fibro-stenosing disease in CD patients.
Investigators also showed that positivity to this antibody remained
constant independently of disease activity [71] and serum ASCA levels
remain stable even after curative intestinal resection [72]. This
suggests that these serological markers may also be used in predicting
risk of disease, progression in patients who are already in remission or
who have already started treatment.
Increased levels of other serological markers, including perinuclear
anti-neutrophil cytoplasmic antibodies (pANCA), Escherichia coli
anti-outer membrane porin-C (OmpC) and anti-flagellin have also
been associated with features of complicated CD, with earlier disease
onset, ileocolonic and perianal disease, penetrating
and stricturing behavior, and increased risk of surgery [73,74].
Schoepfer et al. confirmed the association between anti-flagellin and
ASCA antibodies with complicated CD and showed that patients with
antibodies against multiple microbes have an increased risk of
developing strictures or perforations and an increased risk of requiring
small bowel surgery than patients with antibodies against only one
microbe [75].
Pancreatic autoantibodies are CD specific antibodies which have
been shown to be associated with perforating, perianal disease and
extra-intestinal manifestations in an Eastern European cohort [76]. In
addition, glycoprotein 2 (GP2) has recently been discovered as a major
autoantigen of CD-specific pancreatic autoantibodies (PAB).
Antibodies to GP2 have been shown to be more prevalent in CD
patients with stricturing behavior and perianal disease [77].
Patients having antibodies against multiple microbes have an
increased immune reactivity and this may explain the increased risk of
complicated CD in these patients [75,78]. Mow et al. [79], analyzed the
sera from 303 CD patients for antibodies to I2 (Pseudomonas
fluorescens-related protein), OmpC, ASCA and pANCA and
compared them with disease phenotype. Patients with antibodies to I2
had a significantly increased risk of developing fibro-stenosing disease
and require small intestinal surgery while patients with antibodies to
OmpC had an increased likelihood of internal perforating disease and
small bowel surgery. The risk of small bowel surgery increased
significantly in patients who were triple positive to ASCA, I2 and
OmpC (odds ratio=8.6).
Serological
Marker
Severity of Crohn's Disease References
anti-GM-CSF Stricturing Ileal Disease
Generalized Stricturing and
penetrating disease
Dykes et al. [63]
Gathungu et al.
[65]
ASCA-IgG Stricturing and penetrating disease
Risk of Surgery
Ileal involvement
Dassopoulos et
al. [67]
Eser et al. [72]
anti- flagellin Small bowel disease
Penetrating and fibrostenosing
disease
Targan et al. [71]
Pancreatic
autoantibodies
Penetrating disease
Perianal disease
Extrainstinal manifestations
Lakatos et al. [76]
anti-GP2 Stricturing and perianal disease Bogdanos et al.
[77]
GM-CSF: Granulocyte-Macrophage Colony-Stimulating Factor; ASCA-IgG: Anti-
Saccharomyces cerevisae Antibody Immunoglobulin G; GP2: Glycoprotein 2
Table 2: Serological Markers of Severity in Crohn’s Disease. Key
markers involved in adaptive mucosal immune response in Crohn’s
disease.
There also appears to be a synergistic effect between innate
immunity (NOD2 mutations) and adaptive immunity (antibodies to
microbial antigens) in increasing the risk of fibro-stenosing CD
phenotype. Ippoliti et al. have shown that NOD2 variants and
antibodies to oligomannan, flagellin, OmpC and I2 synergistically
increase this risk [80]. This synergistic effect may occur because NOD2
mutations frequently result in an increased immunologic response to
microbial antigens. Devlin et al. [81] showed that NOD2 mutations are
associated with an increased adaptive immunologic response with
patients having NOD2 polymorphisms having more positive antibody
tests than patients not carrying these polymorphisms. Patients
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carrying NOD2 mutations also had a significantly higher cumulative
serologic response to ASCA, I2, OmpC and CBir1 antigens than
patients not carrying the NOD2 variants.
The serological markers which predict Crohn’s disease severity are
summarised in Table 2.
Conclusion
Innate and adaptive immunity play a central role in the
pathophysiology of Crohn’s disease. Gene polymorphisms which cause
defects in innate immunity and antibodies to bacterial peptides are
increasingly being recognized as predictors of severe Crohn’s disease
types. Stricturing and penetrating disease types, with their increased
risk of surgery, represent severe, complicated CD. Perhaps the most
studied gene mutations which predict severe CD are the NOD2
polymorphisms, though other gene polymorphisms have also been
associated with severe CD types. Research has shown that CD patients
with two or more polymorphisms have a significantly higher risk of
developing the severe CD phenotype.
Elevated levels of serological markers, including ASCA, anti-
flagellin, OmpC and GM-CSF antibodies also appear to predict the
severe CD phenotype. In addition, the presence of more than one
serological marker in the same patient is associated with an
exponential increase in the risk of complicated CD. Combined defects
in innate and adaptive immunity give a synergistically increased risk of
stricturing and penetrating disease types as shown by the increased
risk of severe CD in patients having both NOD2 polymorphisms and
elevated levels of serological markers.
Though the evidence linking these markers with severe CD is
increasing, there are as yet no strict recommendations as to whether
these patients should undergo early, aggressive immunosuppression
with the “top-down” approach. Through the early use of anti-TNFα
therapy, the risk of developing stricturing and penetrating disease
types, and therefore also the risk of surgery, may be decreased [82].
However, further evidence from randomized controlled trials of the
effect of aggressive immunosuppression in patients with these
biomarkers is needed. Expert consensus opinion on which biomarkers
should be analyzed upon CD diagnosis and how many biomarkers are
required to justify the “top-down” therapeutic approach is required.
The levels at which serological markers will predict an increased risk
for severe CD must also be standardized. In addition, these biomarkers
need to become more easily available before they can be recommended
for routine clinical use.
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